Protein fragment complementation assays (PCAs) with luciferase reporters currently are the preferred method for detecting and quantifying protein-protein interactions in living animals. At the most basic level, PCAs involve fusion of two proteins of interest to enzymatically inactive fragments of luciferase. Upon association of the proteins of interest, the luciferase fragments are capable of reconstituting enzymatic activity to generate luminescence in vivo. In addition to bi-molecular luciferase PCAs, unimolecular biosensors for hormones, kinases, and proteases also have been developed using target peptides inserted between inactive luciferase fragments. Luciferase PCAs offer unprecedented opportunities to quantify dynamics of protein-protein interactions in intact cells and living animals, but successful use of luciferase PCAs in cells and mice involves careful consideration of many technical factors. This chapter discusses the design of luciferase PCAs appropriate for animal imaging, including construction of reporters, incorporation of reporters into cells and mice, imaging techniques, and data analysis.
Introduction
Bioluminescence imaging of intact animals is a powerful technology for detecting and quantifying the spatial and temporal occurrence of cellular and molecular events using luminescent enzyme reporters. Traditionally, luciferase enzymes have been used as reporters of promoter activity and, in the case of firefly luciferase, as an assay for ATP. In contrast to these methods, luciferase protein complementation assays (PCAs) were developed to measure post-translational events such as protein interactions, phosphorylation, and enzymatic cleavage of substrates. Luciferase PCAs have been developed for three major luciferases from firefly (1, 2) , sea pansy (Renilla reniformis) (3, 4) , and the copepod Gaussia (Gaussia princeps) (5) . Several firefly and Renilla luciferase PCAs have been published for use in animals. Although in vivo Gaussia luciferase PCAs have been published only for live cells, this technology should be easily translatable to animal work. This chapter details the steps in developing an in vivo assay based on luciferase protein complementation, including reporter vector design, introduction of reporters into cells and animals, and bioluminescence imaging of the luciferase PCA in live cells and mice, with an emphasis on firefly luciferase.
Animal Imaging Materials
In addition to the items listed above in Section 2.3, the following items are required or suggested for animal imaging.
1. Mice for construction of animal models (nude or SCID for xenografts)
2. Coelenterazine, 10 mg/ml stock in acidified MeOH (0.5% HCL (v/v)), store at -20 • C, dilute to desired concentration immediately before imaging in 40% DMSO/PBS for animal imaging (needed only for Renilla and Gaussia luciferases) 3 . Small animal shaver (Wahl compact cordless trimmer recommended) (optional) 4 . Depiliatory lotion such as Nair or Neet (optional).
Methods

Constructing a Luciferase PCA
1. Select a suitable target for the luciferase PCA. See Note 1 for suggestions regarding PCA target selection.
2. Plan relevant orientation of fusion constructs. It is best to test all reasonable orientations of the fusions, keeping in mind the cellular location of the fusion. See Note 2 for examples of bimolecular protein interaction assays and see Note 3 for unimolecular luciferase PCAs.
3. Select an appropriate luciferase for your assay. Several properties of firefly Renilla, and Gaussia luciferases should be considered in choosing a luciferase enzyme for the PCA (see Table 2 .1 and Note 4).
Design a linker to insert between protein folding domains.
Linkers may be used to control the spacing and freedom of motion for the enzyme fragments relative to the proteins of interests. See Note 5 on linker design. 2. Remove media next day and treat as needed in a minimum volume of fresh media (e.g., 50 μl). To construct a time course of drug treatments, it may be helpful to replace the media then add treatments at 10× to the cells on a single plate in reverse time order. The plate may then be imaged at the completion of the course.
3. For imaging firefly luciferase, add luciferin (for firefly luciferase) to the medium in 1/10 volume at a final concentration of 0.15 mg/ml using a multichannel pipette and low adherence tips. A low volume multichannel reservoir is helpful for reducing luciferin waste. Tip the plate and insert the pipette tip under the fluid level before expelling the luciferin to assure full delivery of the substrate. Rock the plate in a figure-8 motion.
For
Gaussia or Renilla luciferase imaging in cells, albumin in media will cause considerable background luminescence with coelenterazine. To eliminate albumin background with native coelenterazine, short-term treatments may be performed in media lacking albumin, or media may be removed and cells washed with PBS prior to imaging. Add coelenterazine (1:1,000 of 1 mg/ml MeOH stock) in 50 μl PBS per well.
5. After addition of luciferase substrate, take a brief test image of 1-10 s on the IVIS. Use this image to estimate the exposure and binning needed for subsequent images. Typical settings for luciferase complementation imaging would be 0.5-to 1-min exposure at maximum binning. Take subsequent images with the appropriate exposure and binning in serial mode to assure capture of the peak luminescence signal. For firefly luciferase, peak light production from intact cells occurs approximately 5-10 min after substrate addition. Peak bioluminescence from Gaussia or Renilla luciferases occurs rapidly within the first minute after adding coelenterazine. See Section 3.6 for data analysis.
Construction of Mouse Tumor Model
Tumor cells (≈ 1 × 10 6 ) stably expressing the PCA reporter or control reporter are injected in contralateral flanks of the mouse. Tumor cells may be injected subcutaneously or orthotopically, such as in the mammary fat pad. After palpable tumors form, mice should be imaged as below. For alternative approaches to construction of mouse models, see Note 8.
Mouse Imaging
For firefly luciferase imaging, mice should be injected intraperitoneally with luciferin (15 mg/ml stock in PBS, 150 μg/g mouse) 10 min before imaging is to begin. Mice are placed in the isoflurane induction chamber 5 min before imaging, then transferred to the IVIS imaging chamber after they are fully anesthetized. Imaging is performed essentially as for cells (Section 3.3). For Renilla or Gaussia luciferase PCAs, we recommend injection of coelenterazine (2.5 mg/kg dissolved in 40% DMSO in PBS, 50 μl) by tail vein, followed by immediate imaging for 1-5 min (see Note 9).
Region of Interest Analysis
Quantify luminescence (photons/s) in a region of interest (ROI) which encompasses the area of luminescence, keeping a standard ROI for all the mice in the experiment (see Note 10).
Notes
1. Luciferase PCAs could be designed for almost any biochemical event that involves a change in the conformation or association of proteins. Luciferase PCAs can be designed to measure either association or dissociation of the luciferase fragments. (In contrast, only association can be measured with PCAs based on fluorescent proteins such as GFP (6), since this method traps the fragments irreversibly in the bound state.) One important consideration is the availability of agents targeting the pathway of interest, or other strategies (such as mutant forms of the proteins of interest) that will result in an "on" and an "off" state for the PCA. For investigation of new biochemical targets, it is also helpful to prepare a control PCA with related, wellstudied proteins that can be used to help validate the PCA for the new target. PCAs may be more easily designed for proteins that have been demonstrated to permit fusions, such as GFP fusions, without significant perturbation of function.
One very useful application of the luciferase PCA is to adapt a FRET or BRET assay for bioluminescence imaging in mice. The user should note that luciferase PCAs differ from FRET and BRET in that PCAs depend on direct contact of the luciferase fragments to reconstitute enzymatic activity. FRET and BRET, in contrast, generate signals based on proximity of fusion proteins. Consequently, some adjustment of the design of the fusion constructs, such as length of linkers, may be required to convert a FRET or BRET assay to a luciferase PCA.
Our experience with luciferase PCAs indicates that they perform optimally at moderate expression levels, such as those typically achieved in stable cell lines. PCAs necessarily require expression of non-native proteins and should be designed to minimize any impact of the reporter on cell function. Gross over-expression of PCA constructs could, in principle, induce artificially high protein-protein association or enzyme-substrate interactions, for example. As with any fusion protein or transgene, the user should validate by methods other than bioluminescence that the luciferase PCA constructs perform as intended.
2.
Two separate open reading frames are used to express the two fusion proteins in a bimolecular PCA. These may be incorporated into two vectors (which facilitates a mixand-match strategy for co-transfections with other PCA reporters) or in a single plasmid construct (to more closely link expression of the two reporters). The upper pair of constructs shows two interacting cytoplasmic proteins (FRB domain from the mammalian target of rapaymycin (mTOR) and FK506 binding protein (FKBP)), which associate upon binding of the compound rapamycin. This association brings Nfluc and Cfluc into close proximity, reconstituting firefly luciferase activity. In this case, the linkers are 16 amino acids long and contain the motif GGGSSSGGG with restriction sites (2) . The lower pair of constructs shows the 7-transmembrane receptor CXCR4 fused as above to Nfluc, while its cytoplasmic binding partner, β-arrestin 2, is fused to Cfluc with a similar linker consisting of 14 amino acids (20) . Note that the optimal construct orientation for this PCA was with the interacting protein at the N-terminus of Cfluc (20) . The schematic diagram illustrates the concept of bimolecular luciferase complementation for CXCR4-Nfluc and β-arrestin 2-Cfluc. CXCR4-Nfluc binds the chemokine SDF-1, resulting in phosphorylation of the intracellular C-terminal domain of CXCR4 by a G-protein receptor kinase (GRK) and subsequent recruitment of β-arrestin2-Cfluc to reconstitute luciferase activity.
of post-translational modification and important interactions with other binding partners should also be considered. Finally, it is advisable to attempt more than one orientation for fusions identify an optimal design.
3. Luciferase PCAs constructed as a single open reading frame have been used to image of several kinds of biochemical events, including ligand binding, phosphorylation, and proteolytic cleavage events (Fig. 2.2) . See Note 2 for additional advice regarding general construction of PCAs.
4. We generally prefer firefly luciferase PCA for intracellular protein interactions and biosensors because for reasons related to mouse imaging in particular. The more red-shifted light of firefly luciferase ( bioluminescence from this luciferase is more stable over the course of imaging. Luciferin, the substrate for firefly luciferase, has more favorable biodistribution than coelenterazine. In addition, i.p. injection of luciferin is much more reproducible for many investigators than tail vein or intracardiac injection required for coelenterazine. Nevertheless, there are several applications that might benefit from other bioluminescent PCAs. For example, in situations where the firefly luciferase cofactors Mg + and ATP may be limiting, Renilla or Gaussia luciferase may be used successfully, although as yet no specific examples of this exist in the literature. Steric bulk can also be reduced by employing Renilla and especially Gaussia PCAs due to their smaller sizes. Finally, it should be noted that luciferase PCAs are not the only bioluminescent imaging approach to PCAs. β-galactosidase PCAs have been adapted for bioluminescence imaging by using intact firefly luciferase as a secondary reporter for β-galactosidase activity (7, 8) .
Several different strategies have emerged for bisecting various luciferase enzymes. For firefly luciferase, we used a library screening approach to identify fragments of NLuc 2-416 and CLuc 398-550 as the best overall combination of low background and high signal, and we continue to find that this pair is optimal for our assays (2) . Recently, Paulmurugan et al. reported alternative firefly luciferase PCA fragments NLuc 2-398 and CLuc 394-550 that may provide higher signal-to-background for some protein interactions (9) . Two pairs of Renilla luciferase enzyme fragments have been recommended for their performance in PCAs: 1-229 and 230-311 (10), and 1-110 and 111-311 (4). A single recommended Gaussia PCA pair has been reported (5), consisting of NGluc 1-93, CGluc 94-169. (Because native Gaussia luciferase contains a 16 amino acid secretion signal that was removed for the study, the first three amino acids of the Ngluc are MKP, the final three are GIG.) Performance of PCAs is heavily impacted by many factors, so the user should consider testing different pairs of luciferase fragments to optimize signal-to-background for a particular application.
Linkers serve to provide points for restriction site in the
DNA construct and to control distance and flexibility between protein domains in the reporter. Flexible linkers (such as GGGSSGGG flanked by restriction sites necessary for cloning) may be helpful in reducing the interference between separate folding domains. For more constraint, a short tri-glycine linker, or no linker at all, may produce good results. The user should consider hydrophilicity of amino acids, steric bulk, and tendency for secondary structure formation in selecting a linker sequence.
6. To distinguish a true PCA signal from effects that impact luciferase enzyme function, the PCA conditions may be tested on full length luciferase in parallel with the PCA. PCA reporter function then can be normalized to function of the intact enzyme to eliminate general effects on enzyme function. In 96-well plate assays, it may also be necessary to include a transfection control, such as β-galactosidase, or to normalize to total protein in a well by an assay such as sulforhodamine B (11), crystal violet, or BCA (Pierce).
7.
Our own experience is that lentiviral constructs tagged with fluorescent proteins can be used to rapidly and efficiently obtain batch transductants, from which clonal sublines can be generated if needed for optimal performance. Transductions can be performed with two viral vectors simultaneously to generate stable reporter cell lines more rapidly. Lentiviruses significantly reduce the time required for obtaining stable lines compared with traditional plasmid strategies. Use of a selectable marker, linked to the reporter through an IRES, can help assure retention of the reporter in cell culture, as well as provide a means to select for cells expressing the reporter at higher levels. Bimolecular reporters may be introduced with tri-cistronic expression vectors (the third position being occupied by a selection marker), although this strategy commonly results in attenuated expression of mRNA molecules further removed from the promoter. Available drug selection markers include neomycin, hygromycin, blasticidin, and zeocin, among others. Of course, use of selectable markers is not possible in mice, so poorly tolerated constructs may not be retained when these constructs are incorporated into solid tumor models.
To rapidly isolate clonal reporter lines, a batch of cells stably expressing the PCA reporter is seeded in 15-mm dishes at 100-300 cells/dish. After colonies of 50 or more cells form, a grid is drawn on the bottom of the dish with heavy black marker, and the dish is imaged in the IVIS under basal conditions or conditions that activate the PCA to identify luminescent colonies. Placing a layer of aluminum foil, nitrocellulose, or other non-bioluminescent material under the dish in the IVIS enables the grid on the dish to be seen, so that colonies are easily located. Using the grid system, locate the luminescent colony and mark it on the underside of the dish with a colored marker. Clones can be harvested from the dish using cloning rings and trypsin, or by direct "picking" of colonies. A second round of colony selection is helpful to insure stability of the clonal line.
8. For short-term testing of a luciferase PCA, the simplest mouse experiment is to conduct treatment tests within minutes or hours after implanting PCA-expressing cells. This approach depends only on the short-term survival of cells in the animal, so that non-tumorigenic cell lines and transient transfectants can be employed. For this approach we implant (i.p. or s.q.) 5-10 × 10 6 cells in PBS. To produce a more confined locus of cell deposition, cells can be injected in a 1:1 mixture of PBS (or DMEM) and matrigel. Cells bearing a relevant control PCA (non-interacting protein, uncleavable peptide, etc.) should be implanted in a parallel set of mice (for i.p.) or in the contralateral flanks of the mice (for s.q.). Stable cell lines expressing PCAs can be easily used to construct mouse models by implanting luciferase PCA cell lines to form tumors. Cells may be injected subcutaneously to form flank tumors, or in relevant physiologic sites, such as the mammary fat pad for breast tumor lines. In principle, PCA constructs could also be introduced to mice directly, by construction of transgenic animals or infection with viral vectors, for example, although such assays are not reported in the literature as yet.
In calculating numbers of cells needed to obtain a detectable signal, the user should consider the depth and optical properties of the tissue through which the light will pass. As a rule of thumb, firefly luciferase light will be attenuated approximately tenfold for each centimeter of tissue, but optically dense tissues such as liver will attenuate light much more than skin, bone, or lung. Best results generally will be obtained by maximizing the number of cells and the perfusion of those cells in the mouse. 9. One of the strengths of luciferase imaging in mice is that a mouse can be imaged repetitively, such as before and after a defined pharmacologic intervention. This strategy allows each mouse to serve as its own control, which reduces experimental variations. To perform repetitive imaging of mice, the user should take into account that luciferase levels in mice peak approximately 10 min after i.p. injection, then decline slowly to background levels by ≈ 6 h post injection (12) . Luciferin biodistribution for imaging firefly luciferase PCA can be stabilized for hours or days by using an osmotic pump (Alzet) (13) . This method has the advantage of producing a relatively constant bioluminescence signal in mice, though i.p. injection of luciferin results in higher tissue concentrations of luciferin and increased signal.
Coelenterazine has a more rapid kinetic course in mice. Therefore, maximum imaging signal for Renilla or Gaussia luciferases is obtained immediately after injecting coelenterazine through intravenous or intracardiac routes (14) (15) (16) . In our hands, coelenterazine is not soluble in PBS unless a co-solvent such as DMSO or ethanol is used, though several publications recommend only PBS as a solvent. Injection of a coelenterazine suspension in PBS is not recommended. Biodistribution of coelenterazine in some tissues, such as the intact brain, is limited by drug transport proteins, which can hinder in vivo imaging of Renilla or Gaussia PCAs in some tissues (17) .
Mouse fur attenuates and scatters light, and this effect is most pronounced in black mice. This problem may be overcome by using nude mice or shaving animals over the region(s) of interest for imaging. For black mice, further hair removal with a depiliatory lotion (Nair, Neet) after shaving is helpful. Care should be taken with depiliatories to limit exposure time and abrasion as mouse skin is quite delicate.
10. Software accompanying the imaging equipment is used to perform the region of interest (ROI) analysis. Figure 2.3 shows an example image and quantified luminescence obtained with a firefly PCA in cell culture. The photons detected by the machine are summed over the Fig. 2.3 . Sample firefly luciferase PCA in cell culture. The assay was prepared as described in Section 3.3, using the CXCR4-Nfluc/βAr2-Cfluc pair diagramed in Fig. 2.1 . In this image, the luminescence data appear as a pseudocolor overlay on the plate photo and is adjusted to illustrate the range of luminescence in the plate. The red grid marks superimposed on the image denote the regions of interest, one for each well. Total photons/s are summed over each region and averaged over the quadruplicate samples, to obtain the graphical data on the right of the figure. In this case, the data illustrate the association of the PCA pair upon incubation for 10 min with the chemokine SDF. area of the ROI to obtain data with units of photons/time (s), or photon flux. Maintaining a standard region of interest within an experiment (or series of experiments) is important to facilitate comparison of mouse imaging data. A simple circular, oval, or square ROI is normally sufficient to be used for all the mice within a set (see Fig. 2.4) . It is helpful to image a "blank" mouse injected with luciferin to obtain a background reading if background subtraction is desired. It is important to note that manipulation of the pseudocolor image display does not alter the quantitative data set for emitted photons. The user should manipulate the display range of pseudocolor image to best highlight the luminescence qualities of their sample.
To control for mouse-to-mouse variations, bioluminescence data may be normalized to one of several markers. For firefly luciferase PCAs, data may be normalized to intact Renilla or Gaussia luciferase incorporated into PCA cells. Other useful markers could include fluorescent proteins, such as mPlum or tdTomato (18) (19) (20) , which can be detected using the fluorescence imaging capabilities of the IVIS and appropriate filters. (Care should be taken in fluorescence imaging to account for the red shift imposed by mouse tissue when selecting excitation and emission filters.) Fluorescence imaging is best performed prior to injection of substrates for bioluminescence imaging. Finally, for solid tumors, simple tumor volumes can suffice for normalizing luminescence signals.
